Amedisys (AMED) Stock Forecast & Price Target

$85.95 +0.80 (+0.94%)

(As of 05:41 PM ET)

Amedisys - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
4

Buy
1

Based on 5 Wall Street analysts who have issued ratings for Amedisys in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 4 have given a hold rating, and 1 has given a buy rating for AMED.

Consensus Price Target

$100.67
17.12% Upside

According to the 5 analysts' twelve-month price targets for Amedisys, the average price target is $100.67. The highest price target for AMED is $101.00, while the lowest price target for AMED is $100.00. The average price target represents a forecasted upside of 17.12% from the current price of $85.95.

Get the Latest News and Ratings for AMED and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amedisys and its competitors.

AMED Analyst Ratings Over Time

Type	Current Forecast 12/27/23 to 12/26/24	1 Month Ago 11/27/23 to 11/26/24	3 Months Ago 9/28/23 to 9/27/24	1 Year Ago 12/27/22 to 12/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$100.67	$100.67	$100.67	$103.55
Forecasted Upside	17.12% Upside	10.60% Upside	4.18% Upside	8.69% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Last time you’ll see this priced at $1.00 (Ad)

When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!

Click here to review Tim’s special Holiday offer before it’s too late.

AMED Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMED Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amedisys Stock vs. The Competition

Type	Amedisys	Medical Companies	S&P 500
Consensus Rating Score	2.20	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	18.31% Upside	25,941.43% Upside	13.25% Upside
News Sentiment Rating	Neutral News See Recent AMED News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/29/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Buy ➝ Hold	$101.00 ➝ $101.00	+2.80%
7/25/2024	Cantor Fitzgerald 4 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$101.00 ➝ $101.00	+3.06%
7/1/2024	William Blair 2 of 5 stars	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/26/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform
3/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$97.00 ➝ $100.00	+8.52%
7/31/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$84.00 ➝ $101.00	+11.22%
Has Trump Finally Gone Too Far? (Ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover
7/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/27/2023	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/27/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$97.00 ➝ $101.00	+10.99%
6/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$88.00 ➝ $101.00	+10.99%
6/6/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$96.00 ➝ $81.00	+1.30%
3/14/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	$103.00	+30.43%
1/19/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $125.00	+34.12%
1/5/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$96.00 ➝ $85.00	-1.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:39 PM ET.

AMED Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Amedisys is $100.67, with a high forecast of $101.00 and a low forecast of $100.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
: According to analysts, Amedisys's stock has a predicted upside of 17.12% based on their 12-month stock forecasts.
: Analysts like Amedisys less than other "medical" companies. The consensus rating for Amedisys is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMED compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

This page (NASDAQ:AMED) was last updated on 12/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amedisys (AMED) Stock Forecast & Price Target